コントロール不良の喘息および血中好酸球数増加を有する被験者におけるレスリズマブの研究

基本情報

NCT ID: NCT02452190
ステータス: 完了
試験のフェーズ: 第3相
試験タイプ: 介入
目標被験者数: 468
治験依頼者名: Teva Branded Pharmaceutical Products R&D, Inc.

概要

The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.

対象疾患

Asthma

介入

Reslizumab(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

Teva Branded Pharmaceutical Products R&d(INDUSTRY)

Ppd Development, Lp(INDUSTRY)

実施施設 (18)

Teva Investigational Site 84053

Ginowan, Japan

Teva Investigational Site 84035

Toyoake-shi, Japan

Teva Investigational Site 84039

Amagasaki, Japan

Teva Investigational Site 84031

Tokyo, Japan

Teva Investigational Site 84038

Toyama, Japan

公立昭和病院

Kodaira, Japan

Teva Investigational Site 84045

Kumamoto, Japan

Teva Investigational Site 84032

Tokyo, Japan

Teva Investigational Site 84044

Kobe, Japan

Teva Investigational Site 84043

Mizunami-shi, Japan

Teva Investigational Site 84049

Hakodate, Japan

石川県立中央病院

Kanazawa, Japan

横浜市立みなと赤十字病院

Yokohama, Japan

Teva Investigational Site 84041

Sagamihara, Japan

県立広島病院

Hiroshima, Japan

Teva Investigational Site 84048

Kobe, Japan

Teva Investigational Site 84037

Kishiwada-shi, Japan

富山県立中央病院

Toyama, Japan